JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study

被引：0
|
作者：
Wohltmann, Wendi E. [1 ]
机构：
[1] San Antonio Mil Med Ctr, Dermatol & Pathol, 1100 Wilford Hall Loop, Jbsa Lackland, TX 78236 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [1] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [2] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [3] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [4] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [5] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [6] Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
    Wechsler, Michael E.
    Ford, Linda B.
    Maspero, Jorge F.
    Pavord, Ian D.
    Papi, Alberto
    Bourdin, Arnaud
    Watz, Henrik
    Castro, Mario
    Nenasheva, Natalia M.
    Tohda, Yuji
    Langton, David
    Cardona, Guido
    Domingo, Christian
    Park, Hae Sim
    Chapman, Kenneth R.
    Mao, Xuezhou
    Zhang, Yi
    Khan, Asif H.
    Deniz, Yamo
    Rowe, Paul J.
    Kapoor, Upender
    Khokhar, Faisal A.
    Mannent, Leda P.
    Ruddy, Marcella
    Laws, Elizabeth
    Amin, Nikhil
    Hardin, Megan
    LANCET RESPIRATORY MEDICINE, 2022, 10 (01): : 11 - 25
  • [7] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [8] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [9] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [10] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
12345